Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial

BACKGROUND: Cytotoxic chemotherapy combinations and targeted agents represent established treatment concepts in advanced pancreatic neuroendocrine tumors (PNETs). However, response rates, side effects and outcome data strongly vary among these therapeutic approaches. Head-to-head comparisons between...

Descripción completa

Detalles Bibliográficos
Autores principales: Krug, Sebastian, Kegel, Thomas, Gress, Thomas M., Rinke, Anja, Apostolidis, Leonidas, Jann, Henning, König, Alexander, Hörsch, Dieter, Schrader, Jörg, Ettrich, Thomas J., Richter, Michael, Steighardt, Jörg, Michl, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8588662/
https://www.ncbi.nlm.nih.gov/pubmed/34772353
http://dx.doi.org/10.1186/s12885-021-08900-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8588662/
https://www.ncbi.nlm.nih.gov/pubmed/34772353
http://dx.doi.org/10.1186/s12885-021-08900-7

Ejemplares similares